This discussion isn't about PRV, it's about ODD.
Whether the benefits of ODD can be claimed more than once (on marketing approvals) depend on whether the regulatory authority agrees that the reformulation constitutes a different product. I don't think it's black and white.
IMO.
- Forums
- ASX - By Stock
- Ann: Invex Granted European Orphan Drug Designation for TBI
This discussion isn't about PRV, it's about...
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.062 |
1 | 15500 | 0.061 |
1 | 150000 | 0.060 |
1 | 100000 | 0.052 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 10000 | 1 |
0.069 | 16500 | 1 |
0.070 | 40000 | 1 |
0.076 | 888 | 1 |
0.083 | 4000 | 1 |
Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable